Aperio Group’s Celldex Therapeutics CLDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-8
Closed 2398
2019
Q2
$0 Buy
+8
New +$27 ﹤0.01% 3027
2016
Q4
Sell
-786
Closed -$48K 2120
2016
Q3
$48K Buy
+786
New +$48.9K ﹤0.01% 2043
2016
Q1
Sell
-1,644
Closed -$387K 2034
2015
Q4
$387K Buy
1,644
+85
+5% +$18.5K ﹤0.01% 1468
2015
Q3
$246K Sell
1,559
-285
-15% -$80.7K ﹤0.01% 1659
2015
Q2
$698K Buy
1,844
+312
+20% +$124K 0.01% 1142
2015
Q1
$640K Sell
1,532
-16
-1% -$5.72K 0.01% 1142
2014
Q4
$424K Buy
1,548
+24
+2% +$5.97K 0.01% 1321
2014
Q3
$296K Buy
+1,524
New +$332K ﹤0.01% 1402

Other funds holding CLDX

Aperio Group's CLDX Position: Q3 2019 in Review

Aperio Group sold out of Celldex Therapeutics (CLDX) in Q3 2019, closing a stake of 8 shares.

Aperio Group first reported a position in CLDX in Q3 2014 and held it in 8 quarters. The position peaked at $698K in Q2 2015. 54 funds tracked by Wall St. Rank hold CLDX as of Q3 2019.

  • Aperio Group reported no remaining Celldex Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Aperio Group sold 8 Celldex Therapeutics shares in Q3 2019.
  • Aperio Group first reported a position in Celldex Therapeutics in Q3 2014 and held it in 8 quarters.
  • Aperio Group's Celldex Therapeutics position peaked at $698K in Q2 2015.
  • 54 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.